Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Raul Parra Jr., the Chief Financial Officer and Treasurer of Merit Medical Systems Inc. (NASDAQ:MMSI), a $6.08 billion medical device company, recently executed a significant stock transaction. According to a recent SEC filing, Parra sold 12,451 shares of Merit Medical (TASE:BLWV) stock on February 28, 2025, at a weighted average price of $98.81 per share. This transaction amounted to a total of approximately $1.23 million, occurring as the stock trades at a P/E ratio of 50.2.
Additionally, on February 27, Parra acquired 20,760 shares at no cost, as part of a performance stock unit issuance. The following day, he acquired another 7,840 shares through a restricted stock unit grant, also at no cost. These acquisitions increased his total holdings to 24,201 shares following the transactions. According to InvestingPro, analysts maintain price targets ranging from $111 to $128, with the company showing GREAT overall financial health.
It’s noteworthy that Parra also surrendered 8,309 shares to cover payroll taxes, valued at $98.5 per share, which equated to $818,436. These shares were not sold on the open market. The stock has delivered a strong 34.7% return over the past year, though current valuations suggest it may be trading above its Fair Value.
In other recent news, Merit Medical Systems , Inc. reported fourth-quarter earnings that exceeded analyst expectations, with earnings per share (EPS) reaching $0.93, surpassing the forecast of $0.82. The company’s revenue for the quarter also exceeded expectations, totaling $355.2 million. Analysts from Oppenheimer, Needham, and Raymond (NSE:RYMD) James have all adjusted their price targets for Merit Medical to $116, reflecting confidence in the company’s recent performance. Despite the positive earnings, Merit Medical’s EPS guidance for the upcoming period fell slightly below consensus expectations, influenced by accounting changes related to convertible securities.
The company’s recent acquisitions, including Cook Medical and EndoGastric Solutions, have reportedly performed beyond initial expectations. Merit Medical has provided optimistic guidance for 2025, projecting revenue growth between 8% and 10%, with a focus on expanding gross margins. The company’s free cash flow saw a significant increase, reaching $185 million for the year, marking a 67% year-over-year improvement.
Merit Medical’s WRAPSODY system is anticipated to generate $7-9 million in revenue in 2025, with increasing contributions expected throughout the year. Analysts from Raymond James believe that Merit Medical is well-positioned to exceed its financial objectives and continue delivering shareholder value. The company remains focused on strategic initiatives and market expansion to sustain its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.